Cartiva Implant Lawsuit [2026 Update]

A federal judge has appointed more than a dozen plaintiffs’ attorneys to leadership roles in the developing Cartiva implant litigation.

The appointments followed an initial organizational hearing held August 26 before Chief U.S. District Judge Kristine G. Baker.

Federal Cartiva lawsuits are centralized in MDL No. 3172 in the U.S. District Court for the Eastern District of Arkansas.

The litigation involves claims that the Cartiva Synthetic Cartilage Implant, used to treat big toe arthritis, failed prematurely and caused complications including implant subsidence, displacement and nerve damage.

The device was recalled in 2024.

Ahead of the hearing, both plaintiffs’ and defense counsel submitted proposals for organizing the litigation, along with case status summaries and proposed discovery schedules.

The appointed leadership will now guide coordinated pretrial proceedings, including common discovery, motion practice and eventual bellwether trial selection.

A systematic review and meta-analysis compared the Cartiva toe implant with toe fusion surgery for patients with advanced arthritis of the big toe.

The researchers found that both treatments improved pain and function, but fusion produced better long-term pain relief.

The review also found that more research is needed to better understand Cartiva’s long-term revision and complication rates.

Researchers analyzed six studies involving approximately 600 patients, including one randomized trial and five cohort studies.

The review found that Cartiva implants preserved about six degrees of toe dorsiflexion, while patients who underwent fusion generally experienced greater pain relief.

Although the overall rate of additional surgeries was similar between the two groups, a sensitivity analysis suggested Cartiva recipients may have a higher rate of true revision surgery.

The authors cautioned that the available evidence remains limited because most studies included relatively short follow-up periods and varied in design.

The findings add new context to the Cartiva toe implant lawsuit, in which plaintiffs allege the synthetic cartilage implant caused persistent pain, implant failure, and the need for revision surgery.

While the review does not evaluate individual legal claims, it concludes that uncertainty remains regarding long-term complications and revision outcomes, reinforcing the need for additional long-term clinical research as Cartiva toe implant litigation continues.

The federal judge overseeing the Cartiva implant multidistrict litigation has scheduled the first status conference for August 19, 2026, marking the official start of coordinated pretrial proceedings in the newly established MDL.

The hearing will bring together attorneys representing both plaintiffs and defendants to begin organizing the litigation and establish procedures for managing the growing number of cases.

During the conference, the court is expected to address applications for plaintiffs’ leadership appointments, discuss protocols for preserving and exchanging evidence, establish discovery procedures, and consider other case management issues.

The judge may also establish a schedule for future filings, status conferences, and other pretrial deadlines as the litigation moves forward.

The Cartiva MDL was created to consolidate federal lawsuits involving allegations that the synthetic cartilage toe implant failed prematurely, causing chronic pain, implant loosening, bone loss, and the need for revision surgeries or toe fusion procedures.

By centralizing the cases before a single judge, the court aims to coordinate discovery, avoid inconsistent pretrial rulings, and improve the efficiency of the litigation as additional lawsuits continue to be filed.

An Arizona woman has filed a lawsuit against Cartiva Inc., alleging that its synthetic cartilage toe implant failed years after implantation and ultimately required removal, toe-fusion surgery, and several additional procedures.

According to the complaint, Andrea Valentine received a Cartiva implant in her left big toe in December 2018 but experienced chronic pain, stiffness, and limited mobility until the device was removed in May 2024.

The lawsuit claims the failure caused bone loss and toe deformity, necessitating further surgeries.

Valentine alleges that Cartiva overstated the implant’s safety and effectiveness while downplaying reports of device failures from surgeons and patients.

The complaint cites FDA findings that reportedly showed significantly lower real-world success rates than those previously promoted before the device entered the market.

The implant was removed from the market in October 2024 after regulators reviewed an increasing number of adverse event reports.

The case has been transferred to the federal Cartiva multidistrict litigation in the Eastern District of Arkansas, where approximately 20 similar lawsuits are pending.

Valentine seeks compensatory and punitive damages, asserting claims of defective design, failure to warn, negligence, product liability, and breach of warranty.

The Cartiva toe implant litigation continues to grow as new lawsuits allege the device failed to deliver on promises of preserving joint motion and avoiding fusion surgery.

In a recently filed case, a West Virginia woman claims her Cartiva Synthetic Cartilage Implant failed within a year of implantation, causing chronic pain, stiffness, bone loss, and limited mobility.

According to the lawsuit, surgeons were ultimately forced to remove the implant and permanently fuse her big toe joint, the very outcome the device was marketed to help patients avoid.

The complaint comes amid increasing scrutiny of the Cartiva implant following the FDA’s 2024 recall and allegations that actual failure rates were significantly higher than those reported during the approval process.

Plaintiffs contend that Cartiva failed to adequately warn patients and physicians about risks including implant loosening, shrinkage, bone erosion, loss of motion, and the need for revision surgery.

The lawsuit will join the federal Cartiva multidistrict litigation (MDL) in Arkansas, where courts are preparing the litigation for coordinated discovery and future bellwether trials.

As more patients come forward reporting failed implants and subsequent fusion procedures, the outcomes of these early test cases could play a significant role in future settlement discussions.

The Cartiva toe implant litigation is rapidly expanding as more patients come forward alleging that the device failed at rates far higher than originally disclosed.

Following the FDA’s 2024 recall, more lawsuits have been filed, with plaintiffs claiming their complications were not isolated incidents but part of a broader pattern tied to the implant’s design.

Cartiva implant cases have now been consolidated into a multidistrict litigation (MDL) in Arkansas, where the court will oversee coordinated discovery and pretrial proceedings.

This process is designed to streamline common issues across cases and prepare a small group of representative lawsuits, known as bellwether trials, that will test how juries respond to the evidence.

The lawsuits center on allegations that the Cartiva synthetic cartilage implant, marketed as a mobility-preserving alternative to toe fusion surgery, instead failed prematurely in real-world use.

Plaintiffs report issues such as implant migration, joint damage, and worsening pain – often leading to additional surgeries, including the very fusion procedure the device was meant to avoid.

In one case, a plaintiff alleges the implant shifted out of place and deteriorated surrounding joint structures, ultimately requiring permanent fusion.

Claims like this are becoming more common as awareness of the recall spreads.

As the MDL moves forward, the key issue will be whether the manufacturer adequately disclosed the true failure rates and risks associated with the device.

A new product liability lawsuit filed in the U.S. District Court for the Eastern District of North Carolina alleges that Cartiva Inc. misrepresented the performance of its synthetic cartilage implant (SCI) for the big toe.

Plaintiff Marion Bhatt received a Cartiva implant in May 2018 for hallux limitus and hallux rigidus, degenerative arthritis conditions affecting the big toe.

The lawsuit claims the implant failed by May 2023, requiring revision and fusion surgery, followed by a second fusion procedure in August 2025.

The Cartiva implant, approved by the FDA in 2016, was marketed as a low-failure option based on the MOTION Study, a clinical trial of 152 procedures reporting no fragmentation, degradation, or bone loss.

Bhatt’s lawsuit contends that real-world outcomes diverged sharply from the trial, with higher Cartiva revision rates and reports of pain and bone damage.

By 2024, the manufacturer recalled the implant after acknowledging a “higher-than-expected” failure rate.

The complaint references internal knowledge and FDA adverse event reports indicating that the device failed at significantly higher rates than the 13.5% cited by the manufacturer.

A product liability lawsuit filed by Daniel Catanese in the U.S. District Court for the Northern District of Illinois claims his Cartiva Synthetic Cartilage Implant (SCI) migrated out of position, damaged surrounding joints, and ultimately required permanent big toe fusion.

The lawsuit, filed on March 6, 2026, identifies Cartiva Inc. as the sole defendant.

Cartiva SCI implants are polyvinyl alcohol-based hydrogel devices introduced in 2016 as an alternative to big toe fusion for hallux limitus or hallux rigidus.

The devices were intended to preserve flexibility while reducing arthritis-related pain.

The implant has been linked to high failure rates, worsening pain, decreased mobility, and bone erosion, leading to a Cartiva SCI recall in October 2024. Many patients required corrective toe fusion surgery after implant failure.

Catanese received a Cartiva SCI in late 2017.

He reports persistent pain and reduced range of motion despite steroid injections in October 2019 and additional treatments in February 2023.

After the Cartiva recall, surgical removal in November 2024 revealed that the implant had shifted laterally, hollowing out the lateral aspect of the metatarsal head and leaving the dorsal cortex unstable for any subsequent implant. Catanese underwent a bone graft and additional procedures to repair damage.

The lawsuit alleges Cartiva knew or should have known of implant risks, citing concerns about the clinical study used for FDA approval and claims that adverse events and failure rates were underreported.

Cartiva Synthetic Cartilage Implant (SCI) lawsuits are increasing nationwide following reports of high failure rates and severe complications.

Patients allege the polyvinyl alcohol-based hydrogel device, marketed as a motion-preserving alternative to big toe fusion for hallux rigidus, frequently failed to relieve pain, loosened, migrated, or subsided into surrounding bone.

Many required revision surgery or eventual big toe fusion, which permanently eliminates joint movement.

The Cartiva SCI was introduced in 2016 and recalled in October 2024 after post-market data revealed higher-than-expected complication rates. Reported complications include implant loosening, subsidence, displacement, persistent pain, nerve damage, stiffness, and fragmentation.

Studies and clinical reports suggest up to 45% of patients experienced adverse outcomes, substantially exceeding the failure rates initially reported during FDA approval.

Patients who received a Cartiva implant may have experienced revision or removal surgery, chronic pain, and long-term mobility limitations.

Surgeons were advised to monitor recipients for persistent toe pain, swelling, weakness, or restricted movement, and hospitals were instructed to remove remaining implants from inventory.

Federal judges will review whether all Cartiva Synthetic Cartilage Implant (SCI) lawsuits should be consolidated for coordinated pretrial proceedings.

Oral arguments before the U.S. Judicial Panel on Multidistrict Litigation (JPML) are scheduled for January 29, 2026, in San Diego, California.

The Cartiva SCI, approved by the FDA in 2016, was marketed as a motion-preserving alternative to big toe fusion for patients with hallux limitus or hallux rigidus.

Made from polyvinyl alcohol (PVA) hydrogel, the implant was designed to relieve pain while maintaining joint flexibility.

However, post-market data revealed significantly higher failure rates than initially reported, leading to a recall in October 2024.

While Cartiva initially claimed a 13% failure rate, later reports indicate failure may affect up to two-thirds of patients, often necessitating removal surgery and, in many cases, permanent big toe fusion.

Plaintiffs across at least five federal district courts allege the implant failed prematurely, causing loosening, subsidence, pain, and loss of mobility.

The lawsuits assert that the device was defectively designed and that the manufacturer failed to adequately warn patients and medical professionals of known risks.

Several plaintiffs petitioned the JPML for multidistrict litigation (MDL) status, arguing consolidation would streamline discovery, depositions, expert analysis, and pretrial proceedings while preventing inconsistent rulings across courts.

If the JPML approves the MDL, all current and future federal claims will be managed by a single judge for coordinated pretrial proceedings, including discovery and potential early bellwether cases.

A Chicago resident has filed a lawsuit against Cartiva Inc., claiming repeated failures of the Cartiva Synthetic Cartilage Implant (SCI) caused permanent injury.

Michelle Paulsen underwent implantation in both feet to treat hallux limitus and hallux rigidus, forms of degenerative arthritis affecting the big toe. Both implants required surgical removal after causing worsening pain and reduced mobility.

The lawsuit, filed November 13, 2025, in the U.S. District Court for the Northern District of Illinois, alleges Cartiva Inc. misrepresented the success rates of the toe implant to the FDA and the medical community.

The complaint states the manufacturer knew or should have known that design flaws in the PVA hydrogel–based implant contributed to an excessive failure rate but withheld this information from doctors and patients.

Cartiva SCI was FDA-approved in 2016 as an alternative to bone fusion, allowing patients to retain big toe flexibility. Reports of widespread failures prompted a national recall in October 2024.

Removal of the implant often required fusion surgery, the procedure patients had sought to avoid. Estimates suggest up to two-thirds of Cartiva toe implants may fail.

Paulsen’s complaint highlights that adverse effects—including loss of range of motion, bone erosion, implant shrinkage, and impaired walking—were not disclosed in patient materials.

Plaintiffs in multiple federal lawsuits over Cartiva Synthetic Cartilage Implant (SCI) failures have petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate the claims before a single judge in the Southern District of West Virginia.

Oral arguments are pending, and the panel will decide whether coordinated pretrial proceedings are appropriate.

The Cartiva SCI, approved by the FDA in 2016, was marketed as a polyvinyl alcohol (PVA) hydrogel implant designed to preserve big toe joint motion and reduce recovery time for patients with hallux limitus or hallux rigidus.

The device aimed to provide an alternative to traditional big toe fusion, which permanently restricts joint movement.

Following post-market reports and research, Cartiva Inc. issued a recall in October 2024, acknowledging a “higher-than-expected failure rate.”

While the company initially reported a 13% failure rate, later studies and surgeon data indicate that up to two-thirds of patients may experience complications, including implant loosening, subsidence, migration, persistent pain, and the need for revision surgery or permanent toe fusion.

Currently, at least seven federal lawsuits have been filed across five districts, with two in West Virginia and one in Maryland already progressing past initial complaints.

Plaintiffs allege nearly identical issues, asserting the device failed prematurely and caused severe pain, reduced mobility, and risky secondary surgeries.

The proposed MDL would consolidate discovery, pretrial motions, and settlement discussions while allowing each case to remain an individual lawsuit.

Cases not resolved through settlement could later return to their original courts for trial.

Lawyers representing plaintiffs in the Cartiva toe implant lawsuits have selected a settlement mediator to begin negotiations in March 2026.

The mediation will address claims involving the recalled Cartiva Synthetic Cartilage Implant (SCI), a polyvinyl alcohol-based device approved by the U.S. Food and Drug Administration (FDA) in 2016 for treatment of hallux limitus and hallux rigidus, degenerative forms of arthritis affecting the big toe joint.

The Cartiva SCI was designed as an alternative to traditional toe fusion surgery. Despite clinical trial data indicating a 13% failure rate, post-market reports revealed substantially higher rates of implant failure.

The FDA issued a nationwide recall in October 2024 after the company acknowledged elevated failure rates. Patients whose implants fail often require removal and subsequent toe fusion, permanently limiting mobility.

The first Cartiva lawsuit in this mediation phase was filed by Pennsylvania resident Robert J. Didonato.

The complaint alleges that Cartiva Inc. concealed evidence showing real-world failure rates approaching two-thirds of patients, while marketing the device as safe and effective.

The lawsuit seeks damages for persistent pain, reduced mobility, and related medical costs.

Didonato and Cartiva Inc. agreed to engage in formal mediation under the court’s Alternative Dispute Resolution (ADR) program before proceeding to a jury trial.

Judge Lisa Lenihan, a former U.S. magistrate judge in the Western District of Pennsylvania with 20 years of judicial experience, was selected to facilitate the mediation.

Parties will equally share mediation fees, and the initial session is scheduled for March 12, 2026.

The first Cartiva implant trial has been postponed until August 3, 2026, after U.S. District Judge Irene Berger of the Southern District of West Virginia granted a joint motion to extend pretrial proceedings.

The court has ordered the parties to engage in settlement discussions, which must conclude at least 30 days before the final pretrial conference scheduled for July 22, 2026.

A written status report is required within five days of completing mediation to inform the court whether a settlement was reached.

Cartiva toe implants are cylindrical devices made from polyvinyl alcohol-based hydrogel (PVA), marketed as an alternative to fusion surgery for hallux limitus or hallux rigidus.

Patients have reported high failure rates, including severe toe pain, implant loosening, and restricted mobility, often requiring removal and additional surgery.

The complications prompted a recall of Cartiva implants in late 2024.

The first trial involves Tammy May, who received a Cartiva implant in April 2022 to treat degenerative arthritis.

She underwent removal surgery in October 2024 due to severe pain and limited range of motion.

May’s claims, filed in December 2024, are expected to mirror testimony and evidence likely to appear in other Cartiva lawsuits nationwide.